Intravitreal Faricimab for Retinal Vein Occlusion: Real-World Outcomes from the Multicenter FARTURK-RVO Study in Türkiye

Fevzi Akkan, Ebru Görgün, Burak Erden, Yavuz Kamil Bardak, Nigar Şerif, Mahmut Öztürk, Erkan Çelik, Selim Bölükbaşı, Şefik Can İpek, Tahsin Uzundede, Gamze Karataş, Murat Karapapak, Ece Özal, Osman Murat Uyar, Doğukan Cömerter, Mehmet Numan Alp, Serhat Ermiş, Anıl Korkmaz, Murat Arıcı, Mehmet Egemen Karataş, Nursal Melda Yenerel, Halil Özgür Artunay, Ecem Önder-Tokuç, Veysel Levent Karabaş, Melih Ünal, Ziya Kapran, Hakan Özdemir, Akın Çakır · 2026

Read Intravitreal Faricimab for Retinal Vein Occlusion: Real-World Outcomes from the Multicenter FARTURK-RVO Study in Türkiye by Fevzi Akkan, Ebru Görgün, Burak Erden, Yavuz Kamil Bardak, Nigar Şerif, Mahmut Öztürk, Erkan Çelik, Selim Bölükbaşı, Şefik Can İpek, Tahsin Uzundede, Gamze Karataş, Murat Karapapak, Ece Özal, Osman Murat Uyar, Doğukan Cömerter, Mehmet Numan Alp, Serhat Ermiş, Anıl Korkmaz, Murat Arıcı, Mehmet Egemen Karataş, Nursal Melda Yenerel, Halil Özgür Artunay, Ecem Önder-Tokuç, Veysel Levent Karabaş, Melih Ünal, Ziya Kapran, Hakan Özdemir, Akın Çakır (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13424009.txt.

Description

Fevzi Akkan heads a 28-author real-world study of faricimab injections for macular edema caused by retinal vein occlusion, gathered from seventeen centres across Türkiye. The FARTURK-RVO cohort followed seventy patients, split almost evenly between branch and central vein blockages, after at least one injection of the dual-action drug.

About 63% of patients were new to treatment and the rest had switched from other drugs. In new patients the swollen central retina thinned dramatically, from roughly 594 to 287 micrometres by the final visit, and switch patients also improved. Vision scores, eye pressure, injection counts, and side effects were tracked over an average follow-up near twenty-four weeks, giving practising clinicians outcome figures outside trial conditions.

Catalog record

CREATORFevzi Akkan, Ebru Görgün, Burak Erden, Yavuz Kamil Bardak, Nigar Şerif, Mahmut Öztürk, Erkan Çelik, Selim Bölükbaşı, Şefik Can İpek, Tahsin Uzundede, Gamze Karataş, Murat Karapapak, Ece Özal, Osman Murat Uyar, Doğukan Cömerter, Mehmet Numan Alp, Serhat Ermiş, Anıl Korkmaz, Murat Arıcı, Mehmet Egemen Karataş, Nursal Melda Yenerel, Halil Özgür Artunay, Ecem Önder-Tokuç, Veysel Levent Karabaş, Melih Ünal, Ziya Kapran, Hakan Özdemir, Akın Çakır
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE62755
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13424009

Browse the full library · About the Tower of Babel